NCT02028442已完成1 期
A Clinical Study Of Enadenotucirev Administered by Sub-Acute Fractionated Intravenous Injection: Dose Escalation in Metastatic Epithelial Solid Tumours and Randomised Controlled Trial in Metastatic Colorectal Cancer
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- Akamis Bio
- 入组人数
- 61
- 试验地点
- 12
- 主要终点
- Phase 1b - Selection of suitable schedule for repeat cycle IV administration
研究概览
简要总结
This is a multicentre, open-label, Phase I/II study of enadenotucirev in patients with either solid tumour of epithelial origin not responding to standard therapy or for whom no standard treatment exists (Phase I dose escalation stage Single cycle), mCRC not responding to standard therapy (Phase I dose escalation Repeat cycle cohort expansion stage ), mCRC not responding to standard therapy or advanced or metastatic bladder cancer not candidate for chemotherapy (Phase Ib) or mCRC in stable disease or partial response after 3-4 months of first line standard of care chemotherapy (Phase II).
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients must provide written informed consent
- •Age ≥ 18 years and the patient must be at least the legal age limit to be able to give consent within the jurisdiction the study is taking place.
- •ECOG performance status 0 or 1
- •Predicted life expectancy of 3 months or more
- •Ability to comply with study procedures in the Investigator's opinion
- •Recovered to Grade 1 from the effects (excluding alopecia) of any prior therapy for their malignancies
- •Adequate renal function
- •Creatinine ≤ 1.5 mg/dL or calculated creatinine clearance using the Cockcroft-Gault formula ≥ 60 mL/min, or measured creatinine clearance ≥ 60 mL/min, Haematuria: dipstick ≤ 2+
- •Proteinuria: dipstick ≤ 2+
- •Adequate hepatic function
- •Serum bilirubin < 1.5 mg/dL
- •Aspartate transaminase (AST) and alanine transaminase (ALT) ≤ 3x upper limit of normal (ULN)
- •Adequate bone marrow function:
- •Absolute neutrophil count (ANC) ≥ 1.5 x 109/L
- •Platelets ≥ 100 x 109/L
- •Haemoglobin ≥ 100 g/L for UCC and ≥ 90 g/L for other cancers
- •Adequate coagulation tests: international normalised ratio (INR) ≤ 1.5 x ULN
- •For females of childbearing potential (defined as <2 years after last menstruation or not surgically sterile), a negative serum pregnancy test must be documented within 14 days prior to first administration of study treatment
- •For women who are not postmenopausal (24 months of amenorrhea) or surgically sterile (absence of ovaries and/or uterus): agreement to use two adequate methods of contraception, during the treatment period and for at least 3 months after the last dose of study drug
- •For men: agreement to use a barrier method of contraception during the treatment period and for at least 6 months after the last dose of study drug
- •At least 3 weeks since any dose of IV systemic chemotherapy and at least two weeks since any oral dose of capecitabine at the time of first administration of ColoAd
- •Phase I Specific Inclusion Criteria:
- •Dose Escalation Stage only (except Repeat Cycle Cohort):
- •Solid tumour of epithelial origin not responding to standard therapy or for whom no standard treatment exists
- •Dose Expansion Stage Single Cycle and Dose Escalation Stage Repeat Cycle Cohort:
- •mCRC not responding to standard therapy
- •≤ 3 prior lines of systemic therapy for advanced disease OR ≤ 4 prior lines of systemic therapy for advanced disease if one of the 4 lines was an anti EGFR therapy given as a single agent or combined to a previously administered chemotherapy regimen Phase Ib:mCRC not responding to standard therapy
- •no more than 3 prior lines of systemic therapy for advanced disease OR no more than 4 prior lines of systemic therapy for advanced disease if one of the 4 lines was an anti EGFR therapy given as a single agent or combined to a previously administered chemotherapy regimen
- •Advanced or metastatic UCC, who have received a maximum of one chemotherapy-containing regimen and a maximum of one other systemic treatment with biologic agents only.
- •Phase II Specific Inclusion Criteria:
- •Have received 3 - 4 months of first line chemotherapy with either FOLFOX, FOLFIRI or CAPOX, with or without bevacizumab
- •At least one measurable lesion according to RECIST 1.1 criteria
- •Documented partial response or stable disease
- •Eligible to receive chemotherapy with FOLFOX or CAPOX after a short chemotherapy interruption (3 to 4 weeks)
- •Exclusion Criteria for all Patients:
- •Pregnant or breast feeding females;
- •Known history or evidence of significant immunodeficiency due to underlying illness (e.g. human immunodeficiency virus [HIV]/acquired immunodeficiency syndrome [AIDS]) and/or medication (e.g. systemic corticosteroids, or other immunosuppressive medications including cyclosporine, azathioprine, interferons, within the past 4 weeks)
- •Splenectomy
- •Prior allogeneic or autologous bone marrow or organ transplantation
- •Active infections requiring antibiotics, physician monitoring, or recurrent fevers >38.0 degrees centigrade associated with a clinical diagnosis of active infection
- •Active viral disease or known positive serology for HIV, hepatitis B or hepatitis C;
- •Use of the following anti-viral agents: ribavirin, adefovir, lamivudine or cidofovir within 7 days prior to day 1; or pegylated interferon (PEG-IFN) (within 14 days prior to first administration of ColoAd1)
- •Administration of an investigational drug within 28 days prior to first dose of ColoAd1
- •Major surgery within 4 weeks or radiotherapy within 3 weeks prior to first dose of ColoAd1
- •Another primary malignancy within the past 3 years (except for non melanoma skin cancer or cervical cancer in situ)
- •Central nervous system (CNS) metastasis that is symptomatic and/or requires treatment
- •Any condition or illness that, in the opinion of the Investigator or the medical monitor, would compromise patient safety or interfere with the evaluation of the safety of the drug
- •Known allergy to treatment medication or its excipients
- •Any other medical or psychological condition that would preclude participation in the study or compromise ability to give informed consent
- •Phase II Specific
排除标准
- •Progression on first line therapy
- •A complete response on first line therapy
- •Use of first line therapy for longer than 4 months
- •Use of any first line treatment with a chemotherapy regimen other than FOLFOX, FOLFIRI or CAPOX (each with or without bevacizumab)
- •More than 6 weeks since the last administration of 5 FU, capecitabine, oxaliplatin or irinotecan
结局指标
主要结局
Phase 1b - Selection of suitable schedule for repeat cycle IV administration
时间窗: Up to Day 134
Open label assessment of 2 repeat cycle schedules, with expansion cohort at the MTD or MFD with best repeat cycle schedule in advanced/metastatic UBC patients.
Phase 1 - Maximum Tolerated Dose
时间窗: Up to Day 22
- Maximum tolerated dose (MTD) / maximum feasible dose (MFD) of enadenotucirev when administered by sub-acute fractionated IV injection (phase I Dose Escalation) and recommended dose for phase II.
次要结局
未报告次要终点
研究者
研究点 (12)
Loading locations...
相似试验
终止
2 期
Use of Etanercept in the Treatment of Moderate to Severe Lichen PlanusLichen PlanusNCT00285779Stanford University27
招募中
1 期
A Clinical Study to Evaluate the Safety and Efficacy of ETX101 in Infants and Children With SCN1A-Positive Dravet SyndromeDravet SyndromeNCT05419492Encoded Therapeutics47
招募中
1 期
First-line Treatment With Dacomitinib Plus Anlotinib for Patients With Advanced NSCLC With EGFR 21L858R MutationsNon-Small Cell Lung Cancer (NSCLC)NCT05271916Shanghai Chest Hospital140
终止
1 期
Study of the Safety and Efficacy of LHC165 Single Agent and in Combination With PDR001 in Patients With Advanced MalignanciesSolid TumorsNCT03301896Novartis Pharmaceuticals45
尚未招募
2 期
Neoadjuvant SHR-A1811 Plus Adebrelimab in HR Negative/Low & HER2 Low Breast Cancer PatientsUntreated Early-stage or Locally Advanced Breast CancerNCT06592625Suzhou Suncadia Biopharmaceuticals Co., Ltd.60